Reliance Takes a Bold Step into Cancer Care: Acquires Karkinos Healthcare for ₹375 Crore
Reliance Industries, through its subsidiary Reliance Strategic Business Ventures Limited (RSBVL), has completed the acquisition of Karkinos Healthcare for ₹375 crore. This strategic move strengthens Reliance’s foothold in the healthcare sector, specifically targeting the rapidly growing oncology market.
Key highlights of the acquisition:
Focus on Cancer Care: Karkinos, established in 2020, specializes in early detection, diagnosis, and treatment of cancer through technology-driven solutions. It partners with hospitals for comprehensive oncology services, including testing and radiation therapy.
Financial Details: Reliance invested ₹10 crore in equity shares and ₹365 crore in convertible debentures. Post-acquisition, Karkinos became a wholly-owned subsidiary of Reliance.
Strategic Vision: With a 150-bed cancer hospital under development in Manipur, Karkinos aligns with Reliance’s commitment to expanding healthcare accessibility and advancing cancer care in India.
Growth Potential: Karkinos reported a turnover of ₹22 crore in FY 2023, a substantial leap from its earlier years. The acquisition was part of a resolution plan approved by the National Company Law Tribunal (NCLT), requiring no additional regulatory clearances
Comments
Post a Comment